Carol Lambert, Ph.D., is the director of the Office of Scientific Review (OSR) within NCATS’ Office of Grants Management and Scientific Review, where she is responsible for a staff that manages the review of applications, requesting support on a broad variety of research topics. She has been the director since 2018; prior to her current position, Dr. Lambert was the acting director in 2017 and the acting deputy director of OSR from 2012 to 2016. Before becoming OSR director, Dr. Lambert performed a variety of complex reviews as senior scientific review officer (SRO) at NCATS and had primary responsibility for the review of CTSA Program Hub applications from 2015 to 2018.
Dr. Lambert joined NIH in 2002 as an SRO at the National Center for Research Resources (NCRR). At NCRR, she was part of the team that conducted the reviews of the former General Clinical Research Centers. In addition to other duties, Dr. Lambert organized and conducted the site visits and reviews of all eight (now seven) National Primate Research Centers and had a primary leadership role on the review administration of 1,200 biomedical construction awards in 18 meetings for the American Reinvestment and Recovery Act.
Prior to joining NIH, Dr. Lambert was an assistant professor in the Department of Diagnostic Radiology at the University of Maryland Medical Center, where she planned, conducted and published original research in radiopharmaceutical chemistry and the development and evaluation of improved radiopharmaceuticals.
Dr. Lambert earned her bachelor’s degree in history from New York University in New York City and her doctorate in chemistry from Wesleyan University in Middletown, Connecticut. She carried out her postdoctoral research in the Division of Nuclear Medicine at Boston Children’s Hospital and in the Radioisotopes and Radiopharmaceuticals Group of the Medical Department at Brookhaven National Laboratory.
Dr. Lambert’s research interests include radiopharmaceutical chemistry and the development and evaluation of improved small-molecule radiolabeled compounds for in vivo diagnostic imaging (i.e., positron emission tomography [PET] and single-photon emission computed tomography [SPECT]).